Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Ketamine hydrochlorideCat. No. 3131 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride |
Biological Activity
Non-competitive NMDA receptor antagonist (EC50 values are 13.6 and 17.6 μM for NR1/NR2A and NR1/NR2B subunit combinations respectively). Dissociative anesthetic. S-enantiomer (Cat. No. 4379) also available.Technical Data
M.Wt:The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Resources
Other Information
Certificate of Analysis / Safety Data Sheet
References
Anis et al (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br.J.Pharmacol. 79 565. PMID: 6317114.
Pallares et al (1995) Effects of ketamine, a noncompetitive NMDA antagonist, on the acquisition of the lever-press response in rats. Physiol.Behav. 57 389. PMID: 7716221.
Liu et al (2001) Modulation of NMDA receptor function by ketamine and magnesium: part I. Anesth.Pharmacol. 92 1173.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Ketamine hydrochloride, supplier, Non-competitive, NMDA, receptor, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, Dissociative, anesthetic
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
Calcium Imbalance and Neuroprotective Targets
Written by E. Besancon et al
'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
The Neurobiology of Alzheimer's Disease
Written by Alan Palmer
'The Neurobiology of Alzheimer's Disease' summarizes structural and functional changes observed in the progression of AD.
New Products in this Area
Positive allosteric modulator of AMPA
CMPDAPositive allosteric modulator of GluA2 receptors
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.